H. Tilly

SGN-30 (Anti-CD30 monoclonal antibody) is active and well tolerated in patients with refractory or recurrent systemic anaplastic large cell lymphoma (ALCL)

J. Leonard, B. Cheson, C. Haioun, 2004 .

Original Fludarabine alone compared to CHVP plus interferon in elderly patients with follicular lymphoma and adverse prognostic parameters: A GELA study

R. Bouabdallah, N. Brousse, C. Haioun, 2005 .

Diffuse large B-cell lymphoma of Waldeyer's ring has distinct clinicopathologic features: a GELA study.

C. Copie-Bergman, M. Baia, T. Molina, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Original article: HTV-associated non-Hodgkin's lymphomas: Clinical characteristics and outcome. The experience of the French Registry of HIV-associated Tumors

P. Morlat, C. Théodore, M. Raphael, 1991 .

EVALUATION OF CLINICOGENETIC RISK MODELS FOR OUTCOME OF FOLLICULAR LYMPHOMA PATIENTS IN THE PRIMA TRIAL

L. Xerri, P. Feugier, A. Viari, 2017 .

Outcome is not improved by the use of alternating chemotherapy in elderly patients with aggressive lymphoma.

P. Gaulard, C. Gisselbrecht, É. Lepage, 2001, The hematology journal : the official journal of the European Haematology Association.

POLA‐R‐CHP: POLATUZUMAB VEDOTIN COMBINED WITH RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, PREDNISONE FOR PATIENTS WITH PREVIOUSLY UNTREATED DIFFUSE LARGE B‐CELL LYMPHOMA

C. Haioun, N. Bartlett, C. Lee, 2017 .

POLARIX: A PHASE 3 STUDY OF POLATUZUMAB VEDOTIN (POLA) PLUS R‐CHP VERSUS R‐CHOP IN PATIENTS (PTS) WITH UNTREATED DLBCL

G. Salles, J. Friedberg, M. Trněný, 2019, Hematological Oncology.

DURABLE BENEFIT OF RITUXIMAB MAINTENANCE POST‐AUTOGRAFT IN PATIENTS WITH RELAPSED FOLLICULAR LYMPHOMA: 12‐YEAR FOLLOW‐UP OF THE EBMT LYMPHOMA WORKING PARTY LYM1 TRIAL

E. Kimby, N. Schmitz, S. Montoto, 2017 .